Immunitrack receives grant to advance platform to discover and characterize T-cell receptor like antibodies


  • The Innovation Fund's investment: DKK 5.5 million
  • Duration: 2 years
  • Official Title: TLA_FINDER: Platform for discovery and characterization of monoclonal TCR-like antibodies to enable an innovative off-the-shelf cancer immunotherapy.

About Immunitrack

Immunitrack is a spinout from the University of Copenhagen, established in 2013. The overall vision of Immunitrack is to enable better patient care through improved immunotherapy.

The company has a key expertise within MHC/epitope binding assessment and have developed and commercialized a leading in vitro binding assay called NeoScreen. The technology is applicable for a number of applications including cancer immunotherapies, development of novel vaccines, and assessing risks of anti-drug antibody response.

About CCIT-DK, Herlev and Gentofte Hospital

The overall aim of CCIT-DK (National Center for Cancer Immune Therapy, based in Herlev, Denmark) is to significantly improve our ability to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy. CCIT-DK is focused on the development of novel immunological treatments of cancer, with a research profile based on complementary experimental and clinical projects. In 2017 CCIT was appointed national research and competence center for immunotherapy based on a grant from the Danish Cancer Society.